Sitfel Nicolaus Initiates Coverage of Abbott with a "Buy" Rating (ABT)

Sitfel Nicolaus Initiates Coverage of Abbott with a “Buy” Rating (ABT)


Sitfel Nicolaus reported on Friday that they have began coverage of health care product company, Abbott Laboratories(ABT).

The firm has initiated coverage of ABT with a “Buy” rating and $40 price target. This price target suggests a 12% increase from the stock’s current price of $34.95.

Analysts have given the company the “Buy” rating and price target based on the company’s ability to maintain consistent earnings growth.

Abbott Laboratories shares were up 30 cents, or 0.86% during Friday morning trading. The stock has increased 26% in the past year.

The Bottom Line
Shares of Abbott Laboratories(ABT) have a 1.60% yield, based on Friday morning’s price of $34.95.

Abbott Laboratories(ABT) is not recommended at this time, holding a DARS™ Rating of 3.4 out of 5 stars.

Be sure to visit our complete recommended list of the Best Dividend Stocks, as well as a detailed explanation of our ratings system here.

Free Updates

Join over 100,000 investors who get the latest news from

Best Dividend Stocks

Looking for stocks that are poised for growth and pay solid dividends? Visit our list of the:

Best Dividend Stocks

Partner Center

Best CD Rates

Sitting on some extra cash and looking for the most current and profitable CD Rates?

Get The Best CD Rates

14 Day Free Trial

Earn more from your dividend portfolio within the next 14 days.

Sign Up Today